Innovent

Recent Finacing

Series E

Recent Raise

$150M

Innovent Biologics develops biopharmaceuticals for oncology, ophthalmology, autoimmune and cardiovascular diseases, operates GMP-compliant manufacturing meeting CFDA/FDA/EMA standards, with 16 research-stage, 7 clinical (4 Phase III, 1 BLA submitted).